Protocol has triggered a Decentralized Science market rally, spiking ecosystem tokens by +90% after announcing an AI-generated peptide for treating ADHD symptoms. This innovation shortened drug discovery timelines and shifted the DeSci narrative towards utility-driven investments.
The BIO token surged from around $0.018 on April 13 to $0.038 as of today (April 16), marking a +105% increase, with trading volume reaching $720M against a $68M market cap.
By April 2026, the DeSci sector sits at a $315M market cap, with BIO holding a near-20% share, serving as a liquidity anchor for BioDAOs focused on various health conditions.
Capital has been rotating from memecoins to utility-focused tokens, with other DeSci participants such as Vibe, HairDAO, and ResearchHub also posting significant gains alongside BIO.
BIO protocol has surged more than +100% in the past 72 hours after news of an AI-driven, groundbreaking ADHD peptide was announced.
SOURCE: TradingView
IP-NFT Structure: How Community-Owned Intellectual Property Funds Biotech R&D
BIO Protocol operates as a decentralized accelerator, providing a liquidity layer for BioDAOs to fund early-stage research and manage intellectual property, bypassing traditional venture capital and Big Pharma gatekeeping.
Central to this model is the IP-NFT, a tokenized representation of rights to specific scientific research, owned collectively by DAO participants.
The announcement of an ADHD peptide showcases the protocol’s potential. An AI-driven drug discovery process identified a peptide that may improve ADHD symptoms, significantly speeding up discovery compared to traditional methods.
Since its Genesis phase, which initiated liquidity via BIO token contributions, the protocol has facilitated over $50M in research funding, backed by Binance Labs in November 2024, marking a significant validation of the DeSci model.
DeSci Competitive Positioning: BIO Protocol vs. a $350M Sector in Revaluation
By March 2026, the BIO token had fallen over 90% from its peak of $0.88 to around $0.018, a typical pattern for narrative-driven cycles.
BIO aligns with two key 2026 trends: decentralized science funding and real-world asset tokenization, with AI playing a transformative role, especially in drug discovery. The company’s announcement of an ADHD peptide tapped into this momentum.
As AI governance tightens in healthcare and biotech, establishing infrastructure for safety reviews will be essential to building institutional trust in AI-driven discovery, a crucial step for BIO’s DAO as it progresses toward clinical validation.
BIO Protocol Market Snapshot: Key Metrics and Catalysts to Watch
Key technical levels show $0.035 as near-term support and $0.04 as resistance, with the token trading at $0.038 and a +52% 24-hour gain on April 16, 2026. The trading volume was $726M against a $70M market cap, indicating a 10x ratio.
Key catalysts to watch include exchange listings, “Ignition Sales,” and updates on the ADHD peptide’s development.
Attracting co-investment from traditional biotech or academic institutions is crucial for distinguishing this DeSci cycle from the previous hype phase. The future success of BIO Protocol’s funded science will determine its ceiling.
***
Looking to start your trading day ahead of the curve?
Get up to speed before the bell with Bull Whisper—a sharp, daily premarket newsletter packed with key news, market-moving updates, and actionable insights for traders.
Start your day with an edge. Subscribe to Bull Whisper using this link.